Navigation Links
Reportlinker Adds Stem Cell Therapeutics Markets Report
Date:9/24/2009

NEW YORK, Sept. 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0116170/Stem-Cell-Therapeutics-Markets.html

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years.

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

  • Cardiovascular disease

  • Lung disease

  • Arthritis

  • Incontinence

  • Osteoporosis

  • Diabetes

  • Cancer

  • Orthopedics

  • Infertility

  • Alzheimer's disease

  • Burns (severe)

  • Lupus

  • Parkinson's disease

  • Liver failure

  • Multiple sclerosis

  • Critical limb ischemia

  • Crohn's disease

  • Sickle cell disease

  • Multiple myeloma

  • NH lymphoma

  • Leukemia

This report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

  • Aastrom Biosciences

  • Advanced Cell Technologies

  • Brainstorm Cell Therapeutics

  • Celegene

  • ES Cell International

  • Medistem

  • Neostem

  • Opexa Therapeutics

  • Osiris Therapeutics

  • Plureon

  • Regenetech

  • Revivicor

  • Stem Cell Sciences

  • StemLifeLine

  • ThermoGenesis

  • VetCell Bioscience

CHAPTER ONE: EXECUTIVE SUMMARY

Recent Developments

Introduction

Current Stem Cell Therapies

Developmental Stem Cell Therapies

Issues in Stem Cell Research

Stem Cell Forecasts

Market Forecast

The Promise of Stem Cells in Medical Treatment

Types of Stem Cells

Embryonic Stem Cells

Important Developments in ES Cell Research

Adult Stem Cells

Important Developments

Scope and Methodology

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Cancer

Leukemia

Gene Therapy

Multiple Myeloma

Non-Hodgkin's Lymphoma Noncancerous Diseases

Aplastic Anemia

Immunodeficiency

Lupus

Sickle Cell Disease

Other Conditions

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer's Disease

Arthritis

Burns

Cancer

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes

Incontinence

Infertility

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Best Case

Forecasts By Disease Area

Alzheimer's Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

Most Likely Case

Forecasts By Disease Area

Alzheimer's Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

CHAPTER FIVE: COMPANY PROFILES

Aastrom Biosciences

Advanced Cell Technologies

Athersys

Brainstorm Cell Therapeutics

Celegene

ES Cell International

Medistem

MultiCell Technologies, Inc.

Neostem

Nephros Therapeutics, Inc.

Opexa Therapeutics

Osiris Therapeutics

Plureon

Regenetech

Revivicor

Stem Cell Sciences

ThermoGenesis

VetCell Bioscience

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007

Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020

Table 3-4: Types and Features of Urinary Incontinence, 2007

Table 3-5: Types and Causes of Male Infertility, 2007

Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007

Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES

Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007

To order this report:

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0116170/Stem-Cell-Therapeutics-Markets.html

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
2. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
3. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
4. Reportlinker Adds Membrane Bioreactors Report
5. Reportlinker Adds Nanoporous Materials Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanomedicine Report
8. Reportlinker Adds Proteomics: Technologies and Global Markets Report
9. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
10. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
11. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... 2015. --> --> For ... of $29.3 million, or $0.34 loss per share, compared to a ... the same period in 2014. For the year ended December 31, ... $1.05 loss per share, as compared to a net loss of ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):